Market Trends of PD-1 And PD-L1 Inhibitors Industry
PD-1 Inhibitors Segment is Expected to Witness Significant Growth Over the Forecast Period
PD-1 (programmed cell death protein 1) inhibitors, a class of immunotherapy drugs, are significantly impacting the cancer treatment market. These agents have demonstrated substantial clinical benefits across various cancer types and have transformed the treatment landscape, particularly for patients with advanced or metastatic diseases, often outperforming traditional chemotherapy.
PD-1 inhibitors offer numerous advantages: they enhance the immune response, improve survival rates, reduce toxicity, and provide the potential for prolonged responses. Additionally, these inhibitors can be effectively combined with other cancer treatments, including chemotherapy, radiation, targeted therapies, and other immunotherapies. Such combinations have frequently shown synergistic effects, improving response rates and patient outcomes.
Ongoing research is exploring the broader potential of PD-1 inhibitors across various diseases. For instance, in February 2024, a collaborative effort led by researchers from the University of Hong Kong's Department of Microbiology and other esteemed institutions revealed that PD-1-boosted DNA vaccinations could sustain virus-specific CD8+ T cell immunity in an AIDS monkey model.
Similarly, an August 2023 study published by ASH publications highlighted an open-label phase 1/2 trial. This trial examined the combination of Favezelimab (anti-LAG-3) and Pembrolizumab in patients with relapsed Hodgkin lymphoma (cHL) post anti-PD-1 treatment. The findings indicated that heavily pretreated patients, whose cHL progressed after anti-PD-1 therapy, exhibited significant antitumor activity with manageable safety. Furthermore, research from the National Institute of Health in August 2022 emphasized the benefits of adding pembrolizumab (Keytruda) for select patients battling advanced triple-negative breast cancer. Such robust R&D supporting PD-1 therapies is expected to drive market growth.
North American is Expected to Hold a Significant Market Share during the Forecast Period
North America is poised for substantial growth in the PD-1 and PD-L1 inhibitors market over the forecast period. This surge is attributed to the rising incidence of cancers, including skin cancer, urothelial carcinomas, and lung cancers, across the United States, Canada, Mexico, and other regional nations. Furthermore, the region's market expansion is bolstered by active product launches and ongoing research studies.
As the United States grapples with a rising number of melanoma cases, the demand for PD-1 and PD-L1 inhibitors is set to escalate, fueling regional market growth. For context, the American Society of Clinical Oncology's 2023 data projected that 97,610 adults in the United States would be diagnosed with invasive skin melanoma in 2023. Notably, melanoma ranks as the fifth most prevalent cancer in the United States, underscoring the swift uptick in its cases.
Intensified research on PD-1 inhibitors stands as a pivotal driver for market growth. For instance, at the IASLC 2023 World Conference on Lung Cancer in November 2023, results were presented from an analysis of two independent patient cohorts from the United States. These patients, diagnosed with advanced NSCLC and possessing a PD-L1 tumor proportion score (TPS) of 50% or higher, were treated with a PD-1 inhibitor. The findings underscored that PD-1 monotherapy offers a significant long-term survival advantage for patients with advanced NSCLC, especially those with a PD-L1 TPS of 90% or more.
Furthermore, a surge in product launches across the region is set to enhance drug availability, propelling market growth. For instance, in March 2023, the United States FDA greenlit Zynyz (retifanlimab-dlwr), a humanized monoclonal antibody targeting PD-1, for adults battling metastatic or recurrent locally advanced cell carcinoma. In a similar vein, the United States FDA, in September 2022, sanctioned the combination of durvalumab (Imfinzi, AstraZeneca UK Ltd) with gemcitabine and cisplatin for treating adults with locally advanced or metastatic biliary cancer (BTC).
Given these dynamics, the market is set for notable growth during the forecast period, driven by heightened R&D efforts and advancements in cancer treatments across the region.
